Literature DB >> 2322990

Flavone acetic acid distribution in human malignant tumors.

G Damia1, A Freschi, R Sorio, A Braida, G Caruso, M Quaia, S Monfardini, M D'Incalci.   

Abstract

The pharmacokinetics of flavone acetic acid (FAA) after a dose of 4.8 mg/m2 given i.v. over 1 h was investigated in 13 patients with different solid tumors. The mean volume of distribution and clearance were 52 +/- 4 l/m2 and 2.6 +/- 0.2 l/h x m2, respectively. A tumor or metastasis biopsy was obtained from six patients 2 h after the end of infusion. Tumor FAA levels ranged from 39.6 to 148.8 micrograms/g and were similar to those obtained after a therapeutic i.v. dose of 200 mg/kg FAA in animals bearing Pan/03 tumor, which is very sensitive to the drug. Although FAA tumor concentration could be detected only during one interval and we therefore cannot draw a definitive conclusion, differences in the agent's antitumor activity in mice and patients (i.e. very active in the former and inactive in the latter) are apparently not due to discrepancies in drug distribution and pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322990     DOI: 10.1007/bf02940298

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.

Authors:  M C Bibby; J A Double; P M Loadman; C V Duke
Journal:  J Natl Cancer Inst       Date:  1989-02-01       Impact factor: 13.506

2.  Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.

Authors:  R L Hornung; T C Back; D S Zaharko; W J Urba; D L Longo; R H Wiltrout
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

3.  Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.

Authors:  G G Chabot; M C Bissery; T H Corbett; K Rutkowski; L H Baker
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

5.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Enhancement of natural killer activity in human peripheral blood by flavone acetic acid.

Authors:  W J Urba; D L Longo; F A Lombardo; R B Weiss
Journal:  J Natl Cancer Inst       Date:  1988-06-01       Impact factor: 13.506

7.  Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.

Authors:  R H Wiltrout; M R Boyd; T C Back; R R Salup; J A Arthur; R L Hornung
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

8.  Dose-dependent pharmacokinetics of flavone acetic acid in mice.

Authors:  G Damia; M L Zanette; C Rossi; R Mandelli; A Ferrari; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.

Authors:  R Giavazzi; A Garofalo; G Damia; S Garattini; M D'Incalci
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

10.  Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).

Authors:  G Pratesi; C Manzotti; G Damia; M D'Incalci
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

View more
  1 in total

1.  Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.

Authors:  M R Stratford; G J Rustin; M F Dennis; R R Watfa; N Howells; S M O'Reilly
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.